MERIT CRO公司和Mianus Capital基金今天宣布新成立一個由眼科領(lǐng)域中最負(fù)盛名的創(chuàng)新企業(yè)家、臨床醫(yī)生與科學(xué)家組成的聯(lián)合科學(xué)顧問委員會 (SAC)。
眼科科學(xué)顧問委員會將為 MERIT CRO 公司和 Mianus Capital 基金提供尖端生物科技技術(shù)和治療方案的咨詢，幫助二家公司為符合市場與病人的需求提供優(yōu)質(zhì)完備的臨床試驗(yàn)服務(wù)與投資，推動生命科學(xué)創(chuàng)新來改善全球眼科疾病患者的治療。
We are proud to work with this prestigious group of industry leaders that provoides unparalleled experience in both clinical research and innovation.
MERIT CRO公司的創(chuàng)始人與CEO黃一駿博士表示：“我們很榮幸能夠與這個享有盛譽(yù)的行業(yè)領(lǐng)軍團(tuán)隊合作，他們在臨床研究和技術(shù)創(chuàng)新?lián)碛袩o與倫比的豐富經(jīng)驗(yàn)。我們的合作將為改善人們的視力和生活質(zhì)量帶來更多的醫(yī)療創(chuàng)新與突破?！?nbsp;
Having been built by insiders of the drug development ecosystem, our CRO+VC platform offers deep access to KOLs and PIs who are at the forefront of biotech innovation.
Mianus Capital 創(chuàng)始人兼首席執(zhí)行官 Steve Yang 表示:"作為醫(yī)藥研發(fā)生態(tài)圈的內(nèi)部組成，我們的 CRO+VC 平臺有得天獨(dú)厚的條件與生物技術(shù)創(chuàng)新前沿的 KOL 和 PI 專家們進(jìn)行深度地交流, 正是這種深度交流為我們提供了眼科、制藥和生物技術(shù)行業(yè)的透徹認(rèn)知與獨(dú)特見解，支持我們在生命科學(xué)領(lǐng)域中的早期投資，這將推進(jìn)更多變革性的新技術(shù)和治療方法的應(yīng)用"
Mianus Clarity Fund
2023年4月Mianus Captal 和 MERIT CRO 在美國視覺和眼科研究協(xié)會 (ARVO) 2023 年會上宣布聯(lián)合推出首期 Mianus Clarity Fund 風(fēng)投基金致力于推動眼科創(chuàng)新。
我們認(rèn)為由于全球人口老齡化、大量未滿足的醫(yī)療需求、有希望的突破性技術(shù)、強(qiáng)大的進(jìn)入壁壘以及創(chuàng)新產(chǎn)品的有利退出機(jī)會，眼科是一個具有巨大投資機(jī)會的細(xì)分領(lǐng)域。
新成立的眼科科學(xué)顧問委員會 (SAC)由多位眼科領(lǐng)域中最優(yōu)秀的創(chuàng)新企業(yè)家、臨床醫(yī)生和科學(xué)家組成：
Robert Avery, MD
California Retina Consultants, Santa Barbara, California. Founding Partner, Director of Clinical Research, Appointment in the Neuroscience Research Institute; University of California, Santa Barbara, Founder of the California Retina Research Foundation.
David S. Boyer, MD
Retina Vitreous Associates Medical Group, Beverly Hills, California. Senior Partner, Clinical Faculty at the Doheny Eye Institute, USC School of Medicine.
David Brown, MD
Retina Consultants of Texas, Houston, Texas. Founding Partner, Director of Clinical Research, Director of the Greater Houston Retina Research Center, Clinical Professor of Ophthalmology at Baylor College of Medicine, Vice-Chair for Research; Blanton Eye Institute at Houston Methodist Hospital.
Antonio Capone Jr., MD
Associated Retina Consultants, Royal Oak, Michigan. Professor of Biomedical Sciences at Oakland University, and Professor at the European School for Advanced Studies in Ophthalmology, Lugano, Switzerland, Co-Director of the Vision Research-ROPARD Foundation, Co-Director of the Associated Retinal Consultants Vitreoretinal Fellowship Training Program.
Mark S. Humayun, MD, PhD
USC Roski Eye Institute, Los Angelas, California. University Professor of Ophthalmology, Cornelius J. Pings Chair in Biomedical Sciences, Director, Institute for Biomedical Therapeutics, Co-Director USC Roski Eye Institute.
Arshad M. Khanani, MD, MA, FASRS
Sierra Eye Associates, Reno, Nevada. Managing Partner, Director of Clinical Research, Director of Fellowship, Clinical Associate Professor, University of Nevada Reno School of Medicine, Reno, Nevada.
Theodore Leng, MD
Stanford University Medical Center, Palo Alto, California. Associate Professor of Ophthalmology, Director of Clinical and Translational Research, Director of Ophthalmic Diagnostics.
Richard Lindstrom, MD
Minnesota Eye Consultants, Minneapolis, Minnesota. Founding Partner, Adjunct Professor Emeritus at the University of Minnesota Department of Ophthalmology.
Carl D. Regillo, MD, FACS, FASRS
Will Eye Hospital, Bryn Mawr, Pennsylvania. Director of the Retina Service; Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University in Philadelphia.
Charles C. Wykoff, MD., PhD
Retina Consultants of Texas, Houston, Texas. Director of the Retina Consultants of Texas Research Centers, Chairman of the Research and Clinical Trials Committee.
另外還有Sadda博士作為眼科風(fēng)投基金的顧問提供咨詢：
SriniVas R. Sadda, MD
Doheny Eye Institute/ Stein Eye Institute, Pasadena, California. President & Chief Scientific Officer, Stephen J. Ryan-Arnold and Mabel Beckman Foundation Endowed Presidential Chair (Advisor only to Mianus Capital)
聯(lián)系我們,了解我們?nèi)绾芜\(yùn)用專業(yè)的知識和方法幫助您在預(yù)算內(nèi)準(zhǔn)時將產(chǎn)品推向市場。您的成功是我們的首要任務(wù)。
